Chronic immobilisation stress ameliorates clinical score and neuroinflammation in a MOG-induced EAE in Dark Agouti rats: Mechanisms implicated

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Pérez Nievas, Beatriz G ^a,b   García Bueno, Borja ^a,b   Madrigal, José L M ^a,b   Leza, Juan C ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Instituto de Investigación Sanitaria Hospital 12 de Octubre ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CORTICOSTERONE; CYCLOOXYGENASE 2; GELATINASE B; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROSTAGLANDIN E2; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; DRUG DERIVATIVE; MYELIN ASSOCIATED GLYCOPROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; PEROXIDASE; PROSTAGLANDIN D2; PROSTAGLANDIN J2;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC STRESS; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DARK AGOUTI RAT; DISEASE SEVERITY; IMMOBILIZATION STRESS; IMMUNOPATHOGENESIS; LONG TERM EXPOSURE; LYMPHOCYTIC INFILTRATION; MALE; MEDIATOR RELEASE; MYELINATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; EXERCISE; IMMUNOLOGY; LIPID PEROXIDATION; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; RADIOIMMUNOASSAY; SPINAL CORD; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CORTICOSTERONE; DINOPROSTONE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LIPID PEROXIDATION; MALE; MYELIN-ASSOCIATED GLYCOPROTEIN; PEROXIDASE; PROSTAGLANDIN D2; RADIOIMMUNOASSAY; RATS; RESTRAINT, PHYSICAL; SPINAL CORD; STRESS, PHYSIOLOGICAL;

EID: 77957358322     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-60     Document Type: Article

References (58)

1. McQualter JL, Bernard CC. Multiple sclerosis: a battle between destruction and repair. J Neurochem 2007, 100:295-306. 10.1111/j.1471-4159.2006.04232.x, 17101032.
2. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862. 10.1056/NEJMoa073493, 17660530.
3. De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008, 70:1113-1118. 10.1212/01.wnl.0000294325.63006.f8, 18272866.
4. Simmons A. Herpesvirus and multiple sclerosis. Herpes 2001, 8:60-63.
5. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci 2009, 14:4477-4515. 10.2741/3543, 2689399, 19273365.
6. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004, 328:731. 10.1136/bmj.38041.724421.55, 381319, 15033880.
7. Mohr DC, Goodkin DE, Bacchetti P, Boudewyn AC, Huang L, Marrietta P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000, 55:55-61.
8. Heesen C, Gold SM, Huitinga I, Reul JM. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review. Psychoneuroendocrinology 2007, 32:604-618. 10.1016/j.psyneuen.2007.05.002, 17602841.
9. Chandler N, Jacobson S, Esposito P, Connolly R, Theoharides TC. Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice. Brain Behav Immun 2002, 16:757-763. 10.1016/S0889-1591(02)00028-4, 12776697.
10. Teunis MA, Heijnen CJ, Sluyter F, Bakker JM, Van Dam AM, Hof M, et al. Maternal deprivation of rat pups increases clinical symptoms of experimental autoimmune encephalomyelitis at adult age. J Neuroimmunol 2002, 133:30-38. 10.1016/S0165-5728(02)00351-X, 12446005.
11. Levine S, Strebel R, Wenk EJ, Harman PJ. Suppression of experimental allergic encephalomyelitis by stress. Proc Soc Exp Biol Med 1962, 109:294-298.
12. Levine S, Saltzman A. Nonspecific stress prevents relapses of experimental allergic encephalomyelitis in rats. Brain Behav Immun 1987, 1:336-341. 10.1016/0889-1591(87)90036-5, 3502584.
13. Whitacre CC, Dowdell K, Griffin AC. Neuroendocrine influences on experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1998, 840:705-716. 10.1111/j.1749-6632.1998.tb09609.x, 9629297.
14. Steelman AJ, Dean DD, Young CR, Smith R, Prentice TW, Meagher MW, et al. Restraint stress modulates virus specific adaptive immunity during acute Theiler's virus infection. Brain Behav Immun 2009, 23:830-843. 10.1016/j.bbi.2009.03.010, 2710426, 19348911.
15. Steelman AJ, Alford E, Young CR, Welsh TH, Meagher MW, Welsh CJ. Restraint stress fails to render C57BL/6 mice susceptible to Theiler's virus-induced demyelination. Neuroimmunomodulation 2010, 17:109-119. 10.1159/000258694, 19923856.
16. Welsh CJ, Bustamante L, Nayak M, Welsh TH, Dean DD, Meagher MW. The effects of restraint stress on the neuropathogenesis of Theiler's virus infection II: NK cell function and cytokine levels in acute disease. Brain Behav Immun 2004, 18:166-174. 10.1016/S0889-1591(03)00116-8, 14759594.
17. Young EE, Sieve AN, Vichaya EG, Carcoba LM, Young CR, Ambrus A, et al. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity. J Neuroimmunol 2010, 220:79-89. 10.1016/j.jneuroim.2010.01.015, 20167380.
18. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007, 275:71-78. 10.1016/j.mce.2007.05.019, 17630118.
19. O'Connor KA, Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, et al. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res 2003, 991:123-132. 10.1016/j.brainres.2003.08.006, 14575884.
20. Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007, 21:259-272. 10.1016/j.bbi.2006.11.006, 1997278, 17194565.
21. Madrigal JL, Moro MA, Lizasoain I, Lorenzo P, Castrillo A, Bosca L, et al. Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. J Neurochem 2001, 76:532-538. 10.1046/j.1471-4159.2001.00108.x, 11208916.
22. Madrigal JL, Garcia-Bueno B, Moro MA, Lizasoain I, Lorenzo P, Leza JC. Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur J Neurosci 2003, 18:1701-1705. 10.1046/j.1460-9568.2003.02888.x, 14511348.
23. Galea E, Heneka MT, Dello RC, Feinstein DL. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol 2003, 23:625-635. 10.1023/A:1025084415833, 14514020.
24. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC. The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats. Psychopharmacology (Berl) 2005, 180:513-522. 10.1007/s00213-005-2195-5, 15719215.
25. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698-701. 10.1038/9550, 10371510.
26. Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 2003, 5:67-73. 10.1089/152091503763816481, 12725709.
27. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol 2001, 116:40-48. 10.1016/S0165-5728(01)00285-5, 11311328.
28. Drew PD, Chavis JA. The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells. J Neuroimmunol 2001, 115:28-35. 10.1016/S0165-5728(01)00267-3, 11282151.
29. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
30. Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid × receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 148:116-126. 10.1016/j.jneuroim.2003.11.010, 14975592.
31. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51:694-702. 10.1002/ana.10206, 12112074.
32. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002, 3:59-70. 10.1038/sj.gene.6363832, 11960303.
33. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971. 10.1093/brain/awl075, 16632554.
34. Kabat EA, Wolf A, Bezer AE. Rapid Production of Acute Disseminated Encephalomyelitis in Rhesus Monkeys by Injection of Brain Tissue With Adjuvants. Science 1946, 104:362-363. 10.1126/science.104.2703.362, 17780100.
35. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999, 24:511-514. 10.1016/S0896-6273(00)81107-1, 10595504.
36. Leza JC, Salas E, Sawicki G, Russell JC, Radomski MW. The effects of stress on homeostasis in JCR-LA-cp rats: the role of nitric oxide. J Pharmacol Exp Ther 1998, 286:1397-1403.
37. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982, 78:206-209. 10.1111/1523-1747.ep12506462, 6276474.
38. Katsu M, Niizuma K, Yoshioka H, Okami N, Sakata H, Chan PH. Hemoglobin-induced oxidative stress contributes to matrix metalloproteinase activation and blood-brain barrier dysfunction in vivo. J Cereb Blood Flow Metab 2010,
39. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010, 38:376-385. 10.1016/j.nbd.2010.03.008, 20302940.
40. Werner U, Szelenyi I. Measurement of MPO activity as model for detection of granulocyte infiltration in different tissues. Agents Actions 1992, (Spec No):C101-C103.
41. Dhabhar FS, McEwen BS, Spencer RL. Adaptation to prolonged or repeated stress--comparison between rat strains showing intrinsic differences in reactivity to acute stress. Neuroendocrinology 1997, 65:360-368. 10.1159/000127196, 9158068.
42. Ueno N, Murakami M, Tanioka T, Fujimori K, Tanabe T, Urade Y, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001, 276:34918-34927. 10.1074/jbc.M100429200, 11418589.
43. Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009, 106:21807-21812. 10.1073/pnas.0906891106, 19995978.
44. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000, 275:28028-28032.
45. Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, et al. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2. Arthritis Res Ther 2005, 7:R1325-R1337. 10.1186/ar1830, 1297580, 16277686.
46. Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009, 106:21807-21812. 10.1073/pnas.0906891106, 2789753, 19995978.
47. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 2007, 56:2608-2619. 10.1002/art.22794, 17665454.
48. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009, 15:633-640. 10.1038/nm.1968, 19465928.
49. Raikwar HP, Muthian G, Rajasingh J, Johnson CN, Bright JJ. PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2. J Neuroimmunol 2006, 178:76-86. 10.1016/j.jneuroim.2006.05.013, 16844232.
50. Pereira MP, Hurtado O, Cardenas A, Bosca L, Castillo J, Davalos A, et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006, 26:218-229. 10.1038/sj.jcbfm.9600182, 16034372.
51. Ponferrada A, Caso JR, Alou L, Colon A, Sevillano D, Moro MA, et al. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 2007, 132:1791-1803. 10.1053/j.gastro.2007.02.032, 17484875.
52. Koh CS, Gausas J, Paterson PY. Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J Neuroimmunol 1993, 47:141-145. 10.1016/0165-5728(93)90024-S, 8370766.
53. Michelson D, Stone L, Galliven E, Magiakou MA, Chrousos GP, Sternberg EM, et al. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab 1994, 79:848-853. 10.1210/jc.79.3.848, 8077372.
54. Webster Marketon JI, Glaser R. Stress hormones and immune function. Cell Immunol 2008, 252:16-26. 10.1016/j.cellimm.2007.09.006, 18279846.
55. Griffin AC, Lo WD, Wolny AC, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by restraint stress: sex differences. J Neuroimmunol 1993, 44:103-116. 10.1016/0165-5728(93)90273-2, 8496336.
56. Derijk RH, Eskandari F, Sternberg EM. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J Neuroimmunol 2004, 151:180-188. 10.1016/j.jneuroim.2004.02.009, 15145616.
57. Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 1998, 55:66-72. 10.1001/archneur.55.1.66, 9443712.
58. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-945. 10.1002/ana.20743, 16315280.